Stocklytics Platform
Asset logo for symbol INM
InMed Pharmaceuticals
INM77
$4.95arrow_drop_up6.88%$0.30
Penny Stock
Asset logo for symbol INM
INM77

$4.95

arrow_drop_up6.88%

Performance History

Chart placeholder
Key Stats
Open$4.43
Prev. Close$4.50
EPS230.40
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$3.58M
LOWHIGH
Day Range4.43
4.94
52 Week Range0.12
6.21
Ratios
Revenue-
EPS230.40

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About InMed Pharmaceuticals (INM)

INM is a pharmaceutical company with a focus on developing and commercializing cannabinoid-based therapies. The company's primary product is INM-085, a potential treatment for the rare genetic disease epidermolysis bullosa. This condition causes the skin to be extremely fragile and prone to blistering and tearing. INM-085 is designed to alleviate the symptoms of the disease and improve patients' quality of life. In addition to this lead candidate, InMed has a pipeline of other cannabinoid-based therapies in various stages of development.
In terms of its stock price history, INM has experienced some volatility over the years. It initially went public in 2016, and since then, its stock price has had its ups and downs. However, there has been a general upward trend in recent years, reflecting the growing interest in cannabinoid-based therapies. Investors are optimistic about the potential of these products to address a wide range of medical conditions and the potential for significant revenue growth. INM's stock price is closely watched by investors and analysts in the pharmaceutical industry.
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Eric A. Adams B.S. Chem., M.I.B.
Headquarters
Vancouver
Employees
13
Exchange
NASDAQ
add InMed Pharmaceuticals to watchlist

Keep an eye on InMed Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is InMed Pharmaceuticals's (INM) price per share?

The current price per share for InMed Pharmaceuticals (INM) is $4.95. The stock has seen a price change of $0.31 recently, indicating a 6.89% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for InMed Pharmaceuticals (INM)?

For InMed Pharmaceuticals (INM), the 52-week high is $6.21, which is 25.45% from the current price. The 52-week low is $0.12, the current price is 3.99K% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is InMed Pharmaceuticals (INM) a growth stock?

InMed Pharmaceuticals (INM) has shown an average price growth of 2.66% over the past three years. It has received a score of 98 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying InMed Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is InMed Pharmaceuticals (INM) stock price performance year to date (YTD)?

As of the latest data, InMed Pharmaceuticals (INM) has a year-to-date price change of 4.43%. Over the past month, the stock has experienced a price change of 12.53%. Over the last three months, the change has been -14.66%. Over the past six months, the figure is -7.48%.
help

Is InMed Pharmaceuticals (INM) a profitable company?

InMed Pharmaceuticals (INM) has a net income of -$7.68M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 23.94% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -156.58% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , with a revenue growth rate of 11.18%, providing insight into the company's sales performance and growth. The gross profit is $1.1M. Operating income is noted at -$7.91B. Furthermore, the EBITDA is -$7.91M.
help

What is the market capitalization of InMed Pharmaceuticals (INM)?

InMed Pharmaceuticals (INM) has a market capitalization of $3.58M. The average daily trading volume is 4.66, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level